BIO
BIO-RAD LABORATORIES, INC.
+4.39 (+1.16%)383.42USD72.5K成交股數10.6B市值8.4本益比(近四季)4.1股價營收比-0.1%營收年增(近四季)2026-10-29下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 651M+11% | 592M-11% | 653M+1% | 652M+2% | 585M-4% | 668M-2% | 650M+3% | 639M-6% | 611M | 681M | 632M | 681M |
| 營業成本 | 305M | 283M | 310M | 306M | 279M | – | 294M | 283M | 285M | – | 296M | 319M |
| 毛利 | 346M+13% | 309M-10% | 343M-4% | 345M-3% | 306M-6% | 342M-7% | 356M+6% | 355M-2% | 326M | 366M | 336M | 363M |
| 毛利率 | 53.1% | 52.3% | 52.6% | 53.0% | 52.3% | 51.2% | 54.8% | 55.6% | 53.4% | 53.8% | 53.1% | 53.2% |
| 研發費用 | 61.2M | 62.9M | 71.3M | 60.5M | 73.5M | – | 91.0M | 58.9M | 66.4M | – | 43.5M | 65.0M |
| 銷售管理費用 | 212M | 212M | 207M | 208M | 209M | – | 200M | 195M | 215M | – | 201M | 208M |
| 營業利益 | 72.6M+206% | 34.1M | 65.3M+1% | 77.1M-24% | 23.7M-47% | – | 64.5M-29% | 102M+13% | 44.6M | – | 90.9M | 89.6M |
| 營業利益率 | 11.2% | 5.8% | 10.0% | 11.8% | 4.0% | – | 9.9% | 15.9% | 7.3% | – | 14.4% | 13.2% |
| 稅後淨利 | 371M+480% | −527M-26% | −342M-152% | 318M-115% | 64.0M-83% | −716M-305% | 653M+514% | −2.2B+86% | 384M | 350M | 106M | −1.2B |
| 淨利率 | 57.1% | -89.0% | -52.4% | 48.8% | 10.9% | -107.2% | 100.5% | -339.2% | 62.9% | 51.3% | 16.8% | -170.6% |
| 稀釋 EPS | 13.85+505% | -19.55-24% | -12.70-154% | 11.67-115% | 2.29-83% | -25.57-311% | 23.34+541% | -76.26+93% | 13.45 | 12.14 | 3.64 | -39.59 |
| 稀釋股數 | 26.8M | 27.0M | 26.9M | 27.2M | 28.0M | – | 28.0M | 28.4M | 28.5M | – | 29.2M | 29.4M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 517M | 507M | 396M | 369M | 521M | 488M | 410M | 407M | 433M | 404M | 458M | 390M |
| 應收帳款 | 442M | 426M | 465M | 470M | 425M | 453M | 462M | 446M | 445M | 489M | 457M | 492M |
| 存貨 | 781M | 771M | 783M | 799M | 790M | 760M | 804M | 804M | 783M | 781M | 776M | 777M |
| 總資產 | 10.3B | 9.8B | 9.7B | 10.2B | 9.5B | 9.4B | 10.6B | 9.7B | 12.6B | 12.3B | 11.9B | 12.0B |
| 有息負債 | 803M | 803M | 1.2B | 1.2B | 1.2B | 1.2B | 1.2B | 1.2B | 1.2B | 1.2B | 1.2B | 1.2B |
| 總負債 | 3.1B | 2.9B | 3.0B | 3.1B | 2.8B | 2.8B | 3.1B | 2.9B | 3.6B | 3.6B | 3.5B | 3.5B |
| 股東權益 | 7.2B | 6.9B | 6.7B | 7.1B | 6.7B | 6.6B | 7.5B | 6.8B | 9.1B | 8.7B | 8.4B | 8.4B |
| 負債比 | 30.0% | 30.0% | 30.5% | 30.2% | 29.9% | 29.8% | 29.4% | 30.0% | 28.2% | 28.9% | 29.3% | 29.5% |
| 淨現金(現金 − 有息負債) | −286M | −296M | −806M | −832M | −679M | −712M | −790M | −793M | −766M | −795M | −741M | −808M |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 108M | – | – | 130M+86% | – | – | – | 69.8M | – | – | – |
| 資本支出 | – | 30.0M | – | – | 34.4M | – | – | – | 40.2M | – | – | – |
| 自由現金流 | – | 78.1M | – | – | 95.5M+223% | – | – | – | 29.6M | – | – | – |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | 47.8M | – | – | 102M | – | – | – | 4.7M | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | 13.2% | – | – | 16.3% | – | – | – | 4.8% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 2.6B
| Clinical Diagnostics | 1.6B | 60.5% | +1.6% |
|---|---|---|---|
| Life Science | 1.0B | 39.5% | -0.7% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 2.6B | +0.7% | 760M | 29.4% | 27.85 | 375M |
| FY2024 | 2.6B | -3.9% | −1.8B | -71.9% | -65.36 | 290M |
| FY2023 | 2.7B | -4.7% | −637M | -23.9% | -21.82 | 218M |
| FY2022 | 2.8B | -4.1% | −3.6B | -129.5% | -121.79 | 81.6M |
| FY2021 | 2.9B | +14.8% | 4.3B | 145.6% | 140.83 | 536M |
| FY2020 | 2.5B | +10.1% | 3.8B | 149.8% | 126.47 | 476M |
| FY2019 | 2.3B | +1.0% | 1.8B | 76.1% | 58.27 | 359M |
| FY2018 | 2.3B | – | 366M | 16.0% | 12.10 | 156M |